Clinical trials
Granulocyte Colony Stimulating Factor clinical trials
Below are recruiting granulocyte colony stimulating factor clinical trials, each written for real people, not researchers. We’re tracking 34 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07871825RecruitingPhase 4
Study of G-CSF for diminished ovarian reserve in IVF
This study tests a medicine called G-CSF (given as an injection) to see if it helps improve egg quality and IVF success in women with a lower egg supply (diminished ovarian reserve). If you are between 35 and 44 and have been told your egg count is low but not too low, this might be worth exploring.
New York, New YorkAges 35–44 - NCT05817214RecruitingPhase 2
Immunotherapy plus targeted drug for advanced cervical cancer
This Phase 2 trial tests cadonilimab (an immunotherapy medicine) combined with anlotinib (a targeted drug) for advanced or recurrent cervical cancer that has already been treated. It may help shrink tumors or slow cancer growth, especially if the cancer has a measurable area doctors can track.
Wuhan, HubeiAges 18–75 - NCT06221683RecruitingPhase 2
Personalized induction therapy for children with AML based on genetics
This trial tests different induction therapy options based on the specific genetic subtype of a child’s AML and how the leukemia responds early on. The goal is to personalize treatment to improve outcomes and reduce side effects.
Hefei, AnhuiAges Up to 18 years - NCT06316960RecruitingPhase 2
Avapritinib for children with relapsed or resistant CBF-AML and KIT mutation
This trial tests a targeted drug called avapritinib in children and teens with a specific type of leukemia (CBF-AML) that has a KIT gene change and has come back or not responded to treatment. The goal is to see if avapritinib is safe and effective for these patients.
Hefei, AnhuiAges Up to 18 years - NCT05726110RecruitingPhase 3
Selinexor for relapsed or refractory AML in combination treatments
This Phase 3 trial studies selinexor (a medicine that changes signals inside cancer cells) used together with other leukemia treatment regimens for adults whose acute myeloid leukemia (AML) has come back or did not respond to standard therapy. It may help people reach remission or control the disease better than the current approach.
Taiyuan, ShanxiAges 18–60 - NCT07692841RecruitingPhase 3
One dose vs two doses of G-CSF for stem cell donors
This trial compares giving a single dose of G-CSF versus splitting it into two doses to see which works better for collecting stem cells from healthy bone marrow donors. The goal is to find a simpler and possibly more comfortable way to help donors produce enough stem cells for transplant.
Changsha, HunanAges 18–65 - NCT07605416RecruitingPhase 2
Testing New Drug Combination for Plasma Cell Leukemia
This study tests a new combination of medicines to treat plasma cell leukemia, a rare blood cancer. The trial aims to help patients newly diagnosed with this condition by using drugs that work against cancer cells in different ways.
New Haven, ConnecticutAges 18–80 - NCT06708572Recruiting
GCSF after Kasai surgery for biliary atresia
This study tests a medicine called GCSF (helps make white blood cells) in babies who have had Kasai surgery for biliary atresia. It aims to see if GCSF can improve liver function and overall outcomes.
Cairo, Menofia GovernorateAges 3 weeks–1 year - NCT07537400RecruitingPhase 2
Naxitamab plus standard therapy for newly diagnosed high-risk neuroblastoma
This study tests adding two medications (naxitamab and GM-CSF) to standard chemotherapy for children and young adults with newly diagnosed high-risk neuroblastoma, a cancer of nerve cells. The goal is to help the body's immune system fight the cancer more effectively.
JerusalemAges 1–21 - NCT07423728Recruiting
Timing of stem cell booster for healthy donors
This trial tests whether giving a stem cell-mobilizing medicine (G-CSF) at a specific time of day based on your natural sleep/wake rhythm can improve the collection of blood stem cells from healthy donors. It aims to make the donation process more efficient and comfortable.
Zhengzhou, HenanAges 18–55 - NCT07362810RecruitingPhase 2
Adding IL-11 to G-CSF for faster blood cell recovery after transplant
This trial tests whether adding a second drug (IL-11) to the standard G-CSF can help your blood cells recover faster after a stem cell transplant using your own cells. It is for people with multiple myeloma or lymphoma who are about to have this transplant.
Zhengzhou, HenanAges 18–70 - NCT03844360RecruitingPhase 4
Personalized dosing of cancer or infection medicines in children
This trial looks at how to adjust the dose of cancer medicines and/or anti-infection medicines in children who have blood-related cancers. The goal is to make dosing fit each child’s needs while they receive standard treatment.
Xuzhou, JiangsuAges 1 day–18 years - NCT07101445RecruitingPhase 4
Comparing steroids to prevent reactions to motixafortide in multiple myeloma
This trial tests two different steroid medicines (methylprednisolone and dexamethasone) to see which works better at preventing side effects from motixafortide, a drug used to help collect stem cells for a stem cell transplant in people with multiple myeloma.
Atlanta, GeorgiaAges 18 years+ - NCT07046078RecruitingPhase 2
Chemo, radiation, and donor transplant for older adults with high-risk AML
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
Seattle, WashingtonAges 18 years+ - NCT07027748RecruitingPhase 1
Testing a longer treatment of three drugs for neuroblastoma
This trial tests giving a combination of naxitamab, irinotecan, and temozolomide for a longer period to people whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if this approach is safe and effective.
Boston, MassachusettsAges 1–30 - NCT07020533RecruitingPhase 1
CMV vaccine for stem cell transplant recipients
This trial tests a vaccine designed to boost immunity against CMV (a common virus) and prevent active CMV infection in people receiving a half-matched stem cell transplant. It may help protect you from CMV-related complications after transplant.
Duarte, CaliforniaAges 18–75 - NCT07002827Recruiting
Growth factors for early decompensated cirrhosis
This study tests whether a combination of two medicines (G-CSF and darbepoetin) given in one or more cycles can improve the body's immune and metabolic health in people with early-stage decompensated cirrhosis (advanced liver disease with mild complications). It compares these treatments with standard medical care.
New Delhi, National Capital Territory of DelhiAges 18–70 - NCT06928376RecruitingPhase 2
Venetoclax plus chemo vs standard chemo for AML
This trial tests a new combination of venetoclax plus a chemotherapy regimen (called CACAG) against a standard chemotherapy regimen (3+7) for adults with newly diagnosed intermediate- or high-risk AML. The goal is to see if the new combination works better.
Beijing, Beijing MunicipalityAges 14–75 - NCT06649851RecruitingPhase 2
G-CSF to reduce side effects during glioblastoma treatment
This trial is testing whether a drug called G-CSF (which helps boost white blood cells) can help people with glioblastoma who are already receiving standard treatment with radiation and chemotherapy (temozolomide). It aims to see if G-CSF can reduce side effects and improve outcomes.
Boston, MassachusettsAges 18 years+ - NCT05754684RecruitingPhase 2
Immunotherapy with donor NK cells for relapsed neuroblastoma
This trial studies a “quadruple immunotherapy” treatment using donor immune cells (NK cells) to fight neuroblastoma that has come back or did not respond to prior therapy. It may help by boosting the body’s immune attack, but only certain children meet the safety and donor requirements.
Hong KongAges Up to 18 years - NCT06158828RecruitingPhase 1/Phase 2
Natural Killer Cells After Half-Matched Stem Cell Transplant for High-Risk AML
This study tests a new way to prevent leukemia from returning after a half-matched stem cell transplant. It uses specially activated natural killer cells to attack remaining cancer cells. This may help people with high-risk or relapsed AML who have few other options.
St Louis, MissouriAges 18 years+ - NCT02605421RecruitingPhase 2
High-risk neuroblastoma stem cell treatment after initial response
This Phase 2 study tests intensive treatment (high-dose “consolidation”) followed by rescue with your own stem cells for high-risk neuroblastoma. It may help patients keep the cancer from coming back after it has improved or stabilized from initial chemotherapy.
Minneapolis, MinnesotaAges Up to 30 years - NCT06084819RecruitingPhase 2
New drug combo for relapsed AML
This trial tests a new drug combination (venetoclax plus CACAG chemotherapy) for people whose acute myeloid leukemia has come back or not responded to earlier treatments. The goal is to see if this combination can help control the leukemia.
Beijing, Beijing MunicipalityAges 14–75 - NCT06059391RecruitingPhase 2
Vaccine for stem cell donors to prevent CMV
This trial tests whether giving a CMV vaccine to stem cell donors can help protect recipients from CMV infection after transplant. It is for adults with specific blood cancers who are CMV-positive and have a matched related donor.
Duarte, CaliforniaAges 18–75
Hear when a new Granulocyte Colony Stimulating Factor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for granulocyte colony stimulating factor?
- Yes. Clin2 currently lists 34 recruiting granulocyte colony stimulating factor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a granulocyte colony stimulating factor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a granulocyte colony stimulating factor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.